See today's BioWorld Science
To read the full story, subscribe or sign in.
Immuno-oncology

IKS-012, a novel and potent ADC, for the treatment of FRα-positive cancers

Nov. 6, 2024
Iksuda Therapeutics Ltd. disclosed the design of a novel, effective and safe antibody-drug conjugate (ADC), IKS-012, for the potential treatment of folate receptor α (FRα)-positive cancers.
BioWorld Science Conferences AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Cancer Antibody-drug conjugate Immuno-oncology